ARCH BIOPARTNERS INC (ARCH.CA) Stock News

Canada - TSX-V:ARCH - CA03938C1041 - Common Stock

1.06 CAD

+0.04 (+3.92%)

Last: 11/5/2025, 7:00:00 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ARCH.CA Latest News, Press Relases and Analysis

All

Press Releases

13 hours ago - By: Arch Biopartners

Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia

2 months ago - By: Arch Biopartners

Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

3 months ago - By: Arch Biopartners

Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

4 months ago - By: Arch Biopartners

Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)

7 months ago - By: Arch Biopartners

Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

8 months ago - By: Arch Biopartners

Arch Biopartners Closes Non-Brokered Private Placement

8 months ago - By: Arch Biopartners

Arch Biopartners Arranges Non-Brokered Private Placement

9 months ago - By: Arch Biopartners

Arch Biopartners Announces Health Canada No Objection Letter (NOL) Granted for Investigator-Led Phase II PONTiAK Trial Using Cilastatin to Target Drug-Toxin-Related Acute Kidney Injury (AKI)

9 months ago - By: Arch Biopartners

Shares for Interest Debt Settlement

10 months ago - By: Arch Biopartners

Arch Biopartners Announces Ontario Research Ethics Board Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

a year ago - By: Arch Biopartners

Arch Biopartners Announces Dosing of First Patient in Canada in the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

a year ago - By: Arch Biopartners

Arch Biopartners Arranges Non-Brokered Private Placement

a year ago - By: Arch Biopartners

Closes Units for Debt Settlement

a year ago - By: Arch Biopartners

Units for Debt Settlement

a year ago - By: Arch Biopartners

Arch Biopartners Announces Alberta Health Services Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury (CS-AKI)

a year ago - By: Arch Biopartners

Arch Biopartners’ Cilastatin Drug Candidate to Participate in the PONTIAC Phase II Trial Targeting Acute Kidney Injury Caused by Drug Toxins

a year ago - By: Arch Biopartners

Arch Biopartners Closes Non-Brokered Private Placement

a year ago - By: Arch Biopartners

Arch Biopartners Arranges Non-Brokered Private Placement

a year ago - By: Arch Biopartners

Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product

a year ago - By: Arch Biopartners

Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

2 years ago - By: Arch Biopartners

St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

2 years ago - By: Arch Biopartners

UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

2 years ago - By: Arch Biopartners

Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

2 years ago - By: Arch Biopartners

Arch Biopartners Clinical Team Publishes Data from Phase II Trial for LSALT Peptide Targeting Organ Inflammation in Hospitalized Patients Infected with SARS-CoV-2

2 years ago - By: Arch Biopartners

University of Calgary Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

2 years ago - By: Arch Biopartners

Arch Biopartners Announces Dosing of First Patient in Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

2 years ago - By: Arch Biopartners

Arch Biopartners Has Pre-IND Meeting With FDA to Discuss Repurposing Cilastatin as a New Treatment to Prevent Acute Kidney Injury

2 years ago - By: Arch Biopartners

Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

2 years ago - By: Arch Biopartners

Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

2 years ago - By: Arch Biopartners

Grant of Options to Directors and Officers

2 years ago - By: Arch Biopartners

Arch Biopartners Submits Application to Health Canada to Conduct the Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

2 years ago - By: Arch Biopartners

Shares for Interest Debt Settlement

2 years ago - By: Arch Biopartners

Arch Biopartners Submits Application to the Turkish Ministry of Health to Conduct a Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

2 years ago - By: Arch Biopartners

Arch Biopartners Engages Independent Trading Group as Market Maker

2 years ago - By: Arch Biopartners

Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial

3 years ago - By: Arch Biopartners

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

3 years ago - By: Arch Biopartners

Arch Scientist Awarded CIHR Grant to Study the Role of Dipeptidase-1 in Chronic Kidney Disease

3 years ago - By: Arch Biopartners

Shares for Interest Debt Settlement; Grants Options

3 years ago - By: Arch Biopartners

Arch Biopartners Adds Farris Smith as a Strategic Advisor

3 years ago - By: Arch Biopartners

Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials